resume

New AHA Statement on Complementary Medicine in Heart Failure

New AHA Statement on Complementary Medicine in Heart Failure

There are some potentially serious benefits and risks associated with complementary and alternative medicine (CAM) that patients with heart failure (HF) can use to manage symptoms, the American Heart Association (AHA) says in a new scientific statement on the subject. For example, yoga and tai chi may be helpful for people with heart failure, and …

New AHA Statement on Complementary Medicine in Heart Failure Read More »

Perceived discrimination linked to worse recovery after MI in young people

Perceived discrimination linked to worse recovery after MI in young people

Perceived discrimination — unfair treatment because of their race, gender, ethnicity, socioeconomic status, or other factors — in daily life was common among young survivors of myocardial infarction (MI) and was associated with poorer recovery, new research shows. In this study, patients completed three questionnaires assessing perceived discrimination, general mental and physical health, physical health, …

Perceived discrimination linked to worse recovery after MI in young people Read More »

Breaking Down Silos: How One Physician Is Reshaping Medicine |  BioSpace

Breaking Down Silos: How One Physician Is Reshaping Medicine | BioSpace

Dr. Kiana Aran, courtesy of Keck Graduate Institute (KGI) As a young woman in Iran, Dr. Kiana Aran made the choice to study electrical engineering. She didn’t know it at the time, but it would lead her to her true passion: biology. It was also the decision that ultimately led her to achieve significant breakthroughs …

Breaking Down Silos: How One Physician Is Reshaping Medicine | BioSpace Read More »

(PRNewsfoto/Ionis Pharmaceuticals, Inc.)

Ionis Presents Positive Phase 2 Data from Donidalorsen Open-Label Extension Study at the 2022 ACAAI Annual Meeting | BioSpace

Interim Results Show Sustained Reduction in Hereditary Angioedema Attacks and No New Safety Signals in Patients Treated for One Year CARLSBAD, Calif., Nov. 13, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported positive results from a Phase 2 open-label extension (OLE) study evaluating the safety and efficacy of its investigational antisense drug, donidalorsen, …

Ionis Presents Positive Phase 2 Data from Donidalorsen Open-Label Extension Study at the 2022 ACAAI Annual Meeting | BioSpace Read More »